Gemtuzumab Ozogamicin in Treating Older Patients With Previously Untreated Acute Myeloid Leukemia
Status:
Unknown status
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
RATIONALE: Monoclonal antibodies such as gemtuzumab ozogamicin can locate cancer cells and
either kill them or deliver cancer-killing substances to them without harming normal cells.
It is not yet known whether gemtuzumab ozogamicin is more effective than standard supportive
care in treating older patients who have acute myeloid leukemia.
PURPOSE: This randomized phase II/III trial is studying two different gemtuzumab ozogamicin
regimens to see how well they work compared to standard supportive care in treating older
patients with previously untreated acute myeloid leukemia.
Phase:
Phase 2/Phase 3
Details
Lead Sponsor:
European Organisation for Research and Treatment of Cancer - EORTC